Statpedia’s Post

𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝘁𝗼 𝗴𝗿𝗼𝘄 𝗮𝘁 𝗮 17.8% 𝗳𝗿𝗼𝗺 2023 𝘁𝗼 2028 Download Free Sample Report-https://lnkd.in/gkMUtteS The global biosimilars market in terms of revenue was estimated to be worth $29.4 billion in 2023 and is poised to reach $66.9 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028. 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗪𝗼𝗿𝗸𝗶𝗻𝗴 𝗶𝗻 𝘁𝗵𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 Sandoz Actavis plc (now Allergan) Fresenius Kabi mAbxience Mundipharma Novartis Italia Alvotech Amgen Italia Novartis Portugal     Polpharma Biologics     Prescient Lek Pharmaceuticals 3P Biopharmaceuticals Napp Pharmaceuticals Limited Synexa Life Sciences Novartis UK Astrea Bioseparations Thornton & Ross  Celonic Group  Egualia – Industrie Farmaci Accessibili Celltrion Healthcare Italia    Amgen Deutschland      ADVANZ PHARMA    ASPHALION Northway Biotech    Antibody Analytics      Novartis Norge QUINTA-ANALYTICA Xbrane Biopharma AB Selexis SA pbserum | Proteos Biotech Profarma Novartis Belux Kymos Inceptua Group Gedeon Richter Pharma GmbH BAP Pharma Formycon AG Eurofins BioPharma Product Testing Netherlands Organon Central Northern Europe

𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝘁𝗼 𝗴𝗿𝗼𝘄 𝗮𝘁 𝗮 17.8% 𝗳𝗿𝗼𝗺 2023 𝘁𝗼 2028 Download Free Sample Report-https://lnkd.in/gkMUtteS The global biosimilars market in terms of revenue was estimated to be worth $29.4 billion in 2023 and is poised to reach $66.9 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028. 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗪𝗼𝗿𝗸𝗶𝗻𝗴 𝗶𝗻 𝘁𝗵𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 Sandoz Actavis plc (now Allergan) Fresenius Kabi mAbxience Mundipharma Novartis Italia Alvotech Amgen Italia Novartis Portugal     Polpharma Biologics     Prescient Lek Pharmaceuticals 3P Biopharmaceuticals Napp Pharmaceuticals Limited Synexa Life Sciences Novartis UK Astrea Bioseparations Thornton & Ross  Celonic Group  Egualia – Industrie Farmaci Accessibili Celltrion Healthcare Italia    Amgen Deutschland      ADVANZ PHARMA    ASPHALION Northway Biotech    Antibody Analytics      Novartis Norge QUINTA-ANALYTICA Xbrane Biopharma AB Selexis SA pbserum | Proteos Biotech Profarma Novartis Belux Kymos Inceptua Group Gedeon Richter Pharma GmbH BAP Pharma Formycon AG Eurofins BioPharma Product Testing Netherlands Organon Central Northern Europe

Biosimilars Market Global Forecast to 2028 ►𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗣𝗗𝗙 𝗕𝗿𝗼𝗰𝗵𝘂𝗿𝗲-https://lnkd.in/gkMUtteS The global biosimilars market in terms of revenue was estimated to be worth $29.4 billion in 2023 and is poised to reach $66.9 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028. Sandoz Teva Pharmaceuticals   Actavis plc (now Allergan)    Fresenius Kabi Dr. Reddy's Laboratories Fresenius Kabi USA Alvogen Amneal Pharmaceuticals Organon Avid Bioservices Association for Accessible Medicines    Kashiv BioSciences LLC Impax Laboratories Lupin Intas Pharmaceuticals  Hetero Sandoz Egypt Mundipharma Novartis Italia USV PRIVATE LIMITED Samsung Bioepis EarlyHealth Group Novartis Portugal 3P Biopharmaceuticals Innovent Biologics Lek Pharmaceuticals  Napp Pharmaceuticals Limited  Prestige Biopharma Group (Prestige Biopharma / Prestige Biologics)    Orchid Pharmed Novartis UK Sandoz Canada Emcure Pharmaceuticals Limited Thornton & Ross Celonic Group Egualia – Industrie Farmaci Accessibili Centurion Pharma Algorithme Pharma | An Altasciences Company PT Etana Biotechnologies Indonesia  ADVANZ PHARMA    ASPHALION

Global Ophthalmic Drugs Market size was valued at USD 39.0 Billion in 2022 and is projected to reach USD 68.16 Billion by 2031, growing at a CAGR of 6.4% from 2022 to 2031 according to a new report by Intellectual Market Insights Research. Request sample Report 👉 https://lnkd.in/dzk-PSTu Report Focused on Top Companies: Acucela Inc. Aerie Aerpio Pharmaceuticals. Akorn Pharmaceuticals, Eyegate Pharmaceuticals, Inc. Eyenovia, Inc. EyePoint Pharmaceuticals, EYEVANCE PHARMACEUTICALS LLC Genentech Icon Bioscience, Inc. Kala Kedrion Biopharma  Mati Therapeutics, Inc. Novaliq GmbH Ocular Therapeutix, Inc. Ohr Pharmaceutical Inc. OphthaliX Inc OPHTHOTECH LIMITED Otonomy, Inc. Otsuka Pharmaceutical Companies (U.S.) Regeneron Pharmaceuticals, Inc. Santen  Santen Pharmaceutical Senju Pharmaceutical Co., Ltd.

Biosimilars Market | Growing at CAGR 17.8% 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 👉https://lnkd.in/dX34yU_w The global biosimilars market in terms of revenue was estimated to be worth USD 29.4 billion in 2023 and is poised to reach USD 66.9 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028. Companies From the Market Cromos Pharma    Stelis Biopharma    Samsung Bioepis      Veeda Clinical Research Limited      Cliantha Research Limited      Alvotech     Texwipe  Altasciences    EarlyHealth Group  Amgen Italia   Novartis Portugal Polpharma Biologics     Lek Pharmaceuticals Innovent Biologics      Prescient   Clinexel Life Sciences Pvt Ltd      3P Biopharmaceuticals Generic Pharmaceutical Assocation Napp Pharmaceuticals Limited Prestige Biopharma Group (Prestige Biopharma / Prestige Biologics)      Synexa Life Sciences    Sandoz Canada      Novartis UK Orchid Pharmed     STADA Thornton & Ross   Biologics Consulting    Boston Oncology Organon Central Northern Europe     Astrea Bioseparations    Biocon Biologics  Reliance Life Sciences Pvt. Ltd.      Enzene Biosciences Ltd Celonic Group   Egualia – Industrie Farmaci Accessibili     CuraTeQ Biologics Centurion Pharma     Axantia Celltrion Healthcare Italia   Eurofins Advinus   Amgen Deutschland  

Biosimilars Market Global Forecast to 2028 ►𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗣𝗗𝗙 𝗕𝗿𝗼𝗰𝗵𝘂𝗿𝗲-https://lnkd.in/gkMUtteS The global biosimilars market in terms of revenue was estimated to be worth $29.4 billion in 2023 and is poised to reach $66.9 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028. Sandoz Teva Pharmaceuticals   Actavis plc (now Allergan)    Fresenius Kabi Dr. Reddy's Laboratories Fresenius Kabi USA Alvogen Amneal Pharmaceuticals Organon Avid Bioservices Association for Accessible Medicines    Kashiv BioSciences LLC Impax Laboratories Lupin Intas Pharmaceuticals  Hetero Sandoz Egypt Mundipharma Novartis Italia USV PRIVATE LIMITED Samsung Bioepis EarlyHealth Group Novartis Portugal 3P Biopharmaceuticals Innovent Biologics Lek Pharmaceuticals  Napp Pharmaceuticals Limited  Prestige Biopharma Group (Prestige Biopharma / Prestige Biologics)    Orchid Pharmed Novartis UK Sandoz Canada Emcure Pharmaceuticals Limited Thornton & Ross Celonic Group Egualia – Industrie Farmaci Accessibili Centurion Pharma Algorithme Pharma | An Altasciences Company PT Etana Biotechnologies Indonesia  ADVANZ PHARMA    ASPHALION

Acadia Pharmaceuticals Inc. completes $150M sale of Priority Review Voucher💰 Know complete story - https://lnkd.in/dCbFQDWn Hepion Pharmaceuticals ends merger with Pharma Two B Ltd.🚫 Know complete story - https://lnkd.in/dMSS58Tb Monte Rosa Therapeutics partners with Novartis on MGDs🔬 Know complete story - https://lnkd.in/d4jxZq9D PRT2527 shows early promise in treating lymphoid malignancies🩺 Prelude Therapeutics  Know complete story - https://lnkd.in/dTYRD93F #Acadia #PRVSale #Hepion #PharmaMerger #MonteRosa #Novartis #MGDs #PRT2527 #LymphoidMalignancies

Pharmaceutical Drug Delivery Market Size to Hit US$ 2,206.5 Billion by 2026 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬:https://lnkd.in/gnWUXpjH The size of global pharmaceutical drug delivery market in terms of revenue was estimated to be worth $1,656.9 billion in 2021 and is poised to reach $2,206.5 billion by 2026, growing at a CAGR of 5.9% from 2021 to 2026. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Johnson & Johnson Novartis Roche Pfizer BD GSK Merck & Co., Inc. Sanofi Bayer 3M Antares Pharma Inc. Amgen AbbVie Genmab Gilead Sciences Boehringer Ingelheim AstraZeneca Eli Lilly and Company Teva Pharmaceuticals Bristol Myers Squibb Gerresheimer Küssnacht AG Boston Scientific Nimbus Therapeutics Kite Pharma IDEAYA Biosciences

Intrigued about the recent developments on #denosumab, #ustekinumab, #ranibizumab, and #adalimumab? Look no further than the Pearce IP #BioBlast which reports on global #BioPharma developments weekly. The complex made simple!

This week's Pearce IP #BioBlast features the following (and more!):    - #denosumab: Amgen and Arrotex Pharmaceuticals Partner to Promote Prolia® (denosumab) in Australia - #ranibizumab: Valorum Biologics to launch #Xbrane and STADA Group’s ranibizumab biosimilar in the US - #ustekinumab: Rani Therapeutics to present further clinical data for oral ustekinumab biosimilar (#denosumab) in Australia - AstraZeneca withdraws COVID vaccine (#Vaxzevria®) from EU market - #ranibizumab / #adalimumab: Sandoz biosimilars earnings up 21% in Q1/24 underpinned by ranibizumab & adalimumab launches - Telix Pharmaceuticals Limited & Cardinal Health finalise clinical supply agreement for Actinium-225 Read more: https://lnkd.in/dEHzfhuH   #BioBlast #biosimilars #boutiquelawfirm #australia #patentlaw #awardwinning #pearceip #patents #biopharma #lifesciences #femalefounder